What is Pacira BioSciences, Inc.'s earnings per share (EPS)?

Pacira BioSciences, Inc. (PCRX) reported diluted earnings per share of $0.16 for fiscal year 2025. This represents a 107.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Pacira BioSciences, Inc. (PCRX) Financials

PCRX

Trailing 12 months to June 30, 2026

Revenue $746.2M +5.7% YoY

Net Income $14.6M +111.5% YoY

EPS (Diluted) $0.35 +112.6% YoY

Free Cash Flow $179.5M +53.3% YoY

Market Cap $1.4B as of Oct 10, 2026

Price / Sales 1.9x on $746.2M revenue, trailing 12 months to June 30, 2026

Price / Earnings 99.2x on $14.6M net income, trailing 12 months to June 30, 2026

Price / Book 2.2x on $672.0M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 4, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PCRX SEC filings page.

Pacira BioSciences, Inc. (PCRX) reported $746.2M in revenue over the twelve months to Jun 30, 2026, up 5.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PCRX FY2025 2026-10-03

Revenue kept climbing, but profitability only partly recovered as heavy overhead and shareholder payouts reshaped a cash-generative business.

The 2024–2025 earnings reset was less severe in cash terms than on the income statement: FY2024 operating cash flow was $189M despite a $100M net loss. In FY2025, operating cash flow remained $152M while accounting profit was only $7M, showing cash conversion stayed positive but earnings were heavily influenced by non-cash or timing effects.

Gross margin reached 79.4% in FY2025, yet operating margin was only 2.6%; much of the improvement in product-level profitability was absorbed by costs below production. The rebound from an operating loss to a small operating profit was real, but it did not yet produce broad earnings leverage.

The FY2025 balance-sheet posture was less debt-dependent and more liquid, with debt-to-equity at 0.5x and the current ratio at 4.5x. Yet the company repurchased $148M of stock against just $7M of net income, meaning shareholder distributions exceeded current-year accounting earnings.

Financial Health Signals

Financial Health Score 53/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Pacira BioSciences, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Pacira BioSciences, Inc. has an operating margin of 2.6%, meaning the company retains $3 of operating profit per $100 of revenue. This results in a moderate score of 33/100, indicating healthy but not exceptional operating efficiency. This is up from -10.5% the prior year.

Growth

Pacira BioSciences, Inc.'s revenue grew a modest 3.6% year-over-year to $726.4M. This slow but positive growth earns a score of 44/100.

Leverage

Pacira BioSciences, Inc. has a moderate D/E ratio of 0.54. This balance of debt and equity financing earns a leverage score of 32/100.

Liquidity

With a current ratio of 4.54, Pacira BioSciences, Inc. holds $4.54 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 90/100.

Cash Flow

Pacira BioSciences, Inc. converts 18.8% of revenue into free cash flow ($136.7M). This strong cash generation earns a score of 87/100.

Returns

Pacira BioSciences, Inc. generates a 1.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 29/100. This is up from -12.8% the prior year.

Altman Z-Score Grey Zone

2.33

Pacira BioSciences, Inc. scores 2.33, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($1.4B) relative to total liabilities ($571.8M). This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

8/9

Pacira BioSciences, Inc. passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

N/A

Pacira BioSciences, Inc. reported $7.0M of net income while generating $152.0M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead.

Interest Coverage At Risk

1.10x

Pacira BioSciences, Inc. earns $1.10 in operating income for every $1 of interest expense ($19.2M vs $17.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$192.4M

YoY+6.2%

QoQ+8.5%

5Y CAGR+7.2%

10Y CAGR+10.7%

Pacira BioSciences, Inc. generated $192.4M in revenue in Q2 2026. This represents an increase of 6.2% from the same quarter a year earlier. Against the prior quarter it is up 8.5%.

EBITDA

$25.6M

YoY-28.6%

QoQ-9.4%

5Y CAGR-8.4%

Pacira BioSciences, Inc.'s EBITDA was $25.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 28.6% from the same quarter a year earlier. Against the prior quarter it is down 9.4%.

Net Income

$4.7M

YoY+196.0%

QoQ+59.6%

5Y CAGR-24.6%

Pacira BioSciences, Inc. reported $4.7M in net income in Q2 2026. This represents an increase of 196.0% from the same quarter a year earlier. Against the prior quarter it is up 59.6%.

EPS (Diluted)

$0.12

YoY+209.1%

QoQ+71.4%

5Y CAGR-22.2%

Pacira BioSciences, Inc. earned $0.12 per diluted share (EPS) in Q2 2026. This represents an increase of 209.1% from the same quarter a year earlier. Against the prior quarter it is up 71.4%.

Cash & Balance Sheet

Free Cash Flow

$56.1M

YoY+502.5%

QoQ+144.5%

5Y CAGR+23.4%

Pacira BioSciences, Inc. generated $56.1M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 502.5% from the same quarter a year earlier. Against the prior quarter it is up 144.5%.

Cash & Debt

$205.9M

YoY-31.5%

QoQ+42.7%

5Y CAGR+14.2%

10Y CAGR+5.8%

Pacira BioSciences, Inc. held $205.9M in cash against $363.1M in long-term debt as of Q2 2026.

Shares Outstanding

40M

YoY-11.3%

QoQ+1.3%

5Y CAGR-2.2%

10Y CAGR+0.7%

Pacira BioSciences, Inc. had 40M shares outstanding in Q2 2026. This represents a decrease of 11.3% from the same quarter a year earlier. Against the prior quarter it is up 1.3%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

77.0%

YoY-0.4pp

QoQ-2.4pp

5Y change+3.0pp

10Y change+10.1pp

Pacira BioSciences, Inc.'s gross margin was 77.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.4 percentage points.

Operating Margin

2.2%

YoY-2.5pp

QoQ-1.7pp

5Y change-23.5pp

Pacira BioSciences, Inc.'s operating margin was 2.2% in Q2 2026, reflecting core business profitability. This is down 2.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.7 percentage points.

Net Margin

2.4%

YoY+5.1pp

QoQ+0.8pp

5Y change-11.6pp

10Y change+13.9pp

Pacira BioSciences, Inc.'s net profit margin was 2.4% in Q2 2026, showing the share of revenue converted to profit. This is up 5.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.8 percentage points.

Return on Equity

0.7%

YoY+1.3pp

QoQ+0.2pp

5Y change-2.1pp

10Y change+4.2pp

Pacira BioSciences, Inc.'s ROE was 0.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.2 percentage points.

Capital Allocation

R&D Spending

$30.2M

YoY+7.2%

QoQ+7.7%

5Y CAGR+19.2%

Pacira BioSciences, Inc. invested $30.2M in research and development in Q2 2026. This represents an increase of 7.2% from the same quarter a year earlier. Against the prior quarter it is up 7.7%.

Share Buybacks

YoY-100.0%

QoQ-100.0%

Pacira BioSciences, Inc. repurchased no shares in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

Capital Expenditures

$1.3M

YoY-50.5%

QoQ-51.0%

5Y CAGR-33.9%

10Y CAGR-17.2%

Pacira BioSciences, Inc. invested $1.3M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 50.5% from the same quarter a year earlier. Against the prior quarter it is down 51.0%.

PCRX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PCRX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$746.2M	$726.4M+3.6%	$701.0M+3.9%	$675.0M+1.2%	$666.8M+23.1%	$541.5M+26.0%	$429.6M+2.0%	$421.0M+24.8%	$337.3M+17.7%	$286.6M+3.7%	$276.4M+11.0%	$249.0M+26.0%	$197.7M+131.1%	$85.6M+118.9%	$39.1M+149.1%	$15.7M
Cost of Revenue	$155.2M	$149.7M-12.1%	$170.4M-7.7%	$184.7M-7.3%	$199.3M+42.1%	$140.3M+19.5%	$117.3M+9.9%	$106.7M+22.9%	$86.8M-1.2%	$87.9M-20.2%	$110.1M+53.3%	$71.8M-7.2%	$77.4M+41.4%	$54.8M+70.4%	$32.1M+92.0%	$16.7M
Gross Profit	$591.0M	$576.7M+8.7%	$530.5M+8.2%	$490.3M+4.9%	$467.5M+16.5%	$401.3M+28.5%	$312.3M-0.6%	$314.3M+25.5%	$250.4M+26.0%	$198.7M+19.5%	$166.3M-6.1%	$177.2M+47.4%	$120.2M+290.6%	$30.8M+343.2%	$6.9M+761.4%	-$1.1M
R&D Expenses	$122.1M	$117.3M+43.8%	$81.6M+7.0%	$76.3M-10.1%	$84.8M+52.7%	$55.5M-6.5%	$59.4M-17.6%	$72.1M+29.5%	$55.7M-2.8%	$57.3M+25.4%	$45.7M+59.4%	$28.7M+53.0%	$18.7M-13.1%	$21.6M+117.0%	$9.9M-33.2%	$14.9M
SG&A Expenses	$379.2M	$368.8M+25.4%	$294.1M+9.2%	$269.4M+5.9%	$254.5M+27.7%	$199.3M+3.0%	$193.5M-3.6%	$200.8M+13.3%	$177.3M+9.8%	$161.5M+5.8%	$152.6M+9.8%	$139.0M+30.4%	$106.7M+70.6%	$62.5M+35.0%	$46.3M+129.7%	$20.2M
Operating Income	$19.9M	$19.2M+126.2%	-$73.4M-183.7%	$87.7M+46.1%	$60.0M-33.3%	$89.9M+94.0%	$46.4M+342.3%	$10.5M-34.2%	$15.9M+163.8%	-$24.9M+22.1%	-$32.0M-438.7%	$9.5M+283.1%	-$5.2M+90.3%	-$53.3M-8.1%	-$49.3M-26.1%	-$39.1M
EBITDA	N/A	$110.2M+1935.7%	$5.4M-96.7%	$163.2M+7.7%	$151.5M+27.9%	$118.5M+78.8%	$66.3M+120.4%	$30.1M+3.4%	$29.1M+361.9%	-$11.1M+41.9%	-$19.1M-191.3%	$20.9M+329.8%	$4.9M+110.2%	-$47.5M-8.9%	-$43.6M-25.5%	-$34.8M
Interest Expense	$15.5M	$17.4M+5.3%	$16.6M-18.4%	$20.3M-49.2%	$40.0M+25.9%	$31.8M+23.7%	$25.7M+8.6%	$23.6M+7.6%	$21.9M+21.6%	$18.0M+155.6%	$7.1M-8.6%	$7.7M-6.7%	$8.3M+14.1%	$7.3M+301.4%	$1.8M-62.2%	$4.8M
Income Tax	$3.0M	$9.8M-73.0%	$36.5M+84.6%	$19.7M+857.4%	-$2.6M-118.1%	$14.4M+111.5%	-$125.4M-46903.7%	$268K+482.6%	$46K-67.1%	$140K+33.3%	$105K-60.2%	$264K+52.6%	$173K+139.1%	-$442K	$0	$0
Net Income	$14.6M	$7.0M+107.0%	-$99.6M-337.1%	$42.0M+164.2%	$15.9M-62.1%	$42.0M-71.1%	$145.5M+1421.0%	-$11.0M-2238.9%	-$471K+98.9%	-$42.6M-12.3%	-$37.9M-2144.7%	$1.9M+113.5%	-$13.7M+78.5%	-$63.9M-22.2%	-$52.3M-20.7%	-$43.3M
EPS (Basic)	N/A	$0.16+107.4%	-$2.15-336.3%	$0.91+160.0%	$0.35-63.2%	$0.95-72.1%	$3.41+1363.0%	-$0.27-2600.0%	-$0.01+99.1%	-$1.07-4.9%	-$1.02-2140.0%	$0.05+112.8%	-$0.39+79.8%	-$1.93	N/A	N/A
EPS (Diluted)	$0.35	$0.16+107.4%	-$2.15-341.6%	$0.89+161.8%	$0.34-63.0%	$0.92-72.4%	$3.33+1333.3%	-$0.27-2600.0%	-$0.01+99.1%	-$1.07-4.9%	-$1.02-2650.0%	$0.04+110.3%	-$0.39+79.8%	-$1.93	N/A	N/A
Diluted Shares (Avg)	N/A	45M-2.6%	46M-11.0%	52M+11.7%	47M+2.0%	46M+4.5%	44M+5.2%	42M+1.5%	41M+2.8%	40M+6.9%	37M-9.8%	41M+17.0%	35M+6.4%	33M	N/A	16M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$192.4M+6.2%	$177.4M+5.0%	$196.9M+5.1%	$179.5M+6.5%	$181.1M+1.7%	$168.9M+1.1%	$187.3M+3.3%	$168.6M+2.8%
Cost of Revenue	$44.2M+8.1%	$36.4M+6.1%	$40.3M+1.0%	$34.3M-11.8%	$40.9M-7.7%	$34.3M-27.6%	$39.9M-16.4%	$38.9M-2.2%
Gross Profit	$148.2M+5.7%	$141.0M+4.7%	$156.6M+6.2%	$145.2M+12.0%	$140.2M+4.8%	$134.6M+12.5%	$147.4M+10.3%	$129.7M+4.5%
R&D Expenses	$30.2M+7.2%	$28.1M+10.8%	$37.8M+58.2%	$26.0M+35.9%	$28.2M+38.7%	$25.3M+39.0%	$23.9M+22.8%	$19.1M-8.3%
SG&A Expenses	$91.8M+3.6%	$93.9M+8.3%	$101.6M+27.6%	$91.8M+23.5%	$88.6M+30.0%	$86.8M+20.5%	$79.6M+21.0%	$74.3M+9.4%
Operating Income	$4.3M-49.8%	$6.9M+246.8%	$2.3M-90.5%	$6.4M+104.6%	$8.5M-69.9%	$2.0M-84.9%	$24.7M-25.5%	-$139.5M-887.4%
EBITDA	$25.6M-28.6%	$28.2M+21.9%	$23.7M-48.5%	$27.6M+123.1%	$35.8M-23.9%	$23.2M-26.8%	$45.9M-11.2%	-$119.2M-429.8%
Interest Expense	$3.6M-22.9%	$3.7M-19.2%	$3.9M-16.8%	$4.3M-8.7%	$4.7M+20.9%	$4.6M+38.1%	$4.7M+38.1%	$4.7M+35.4%
Income Tax	-$2.1M-171.8%	$2.1M-46.5%	-$1.1M-111.2%	$4.1M-11.2%	$2.9M-83.5%	$3.9M-16.5%	$9.5M+7.2%	$4.6M-19.7%
Net Income	$4.7M+196.0%	$2.9M-39.4%	$1.6M-90.0%	$5.4M+103.8%	-$4.8M-125.7%	$4.8M-46.4%	$16.0M-35.8%	-$143.5M-1421.3%
EPS (Basic)	$0.12+209.1%	$0.07-30.0%	$0.04-88.6%	$0.12+103.9%	-$0.11-126.8%	$0.10-47.4%	$0.35-35.2%	-$3.11-1452.2%
EPS (Diluted)	$0.12+209.1%	$0.07-30.0%	$0.04-88.6%	$0.12+103.9%	-$0.11-128.2%	$0.10-47.4%	$0.35-32.7%	-$3.11-1452.2%
Diluted Shares (Avg)	40M-11.3%	41M-12.1%	N/A	44M-3.6%	45M-10.1%	47M-10.9%	N/A	46M-11.4%

PCRX Balance Sheet

PCRX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$1.3B-18.6%	$1.6B-1.3%	$1.6B-6.4%	$1.7B-19.0%	$2.1B+62.8%	$1.3B+53.4%	$831.1M+20.6%	$689.4M+9.7%	$628.4M+60.5%	$391.5M+1.0%	$387.7M+18.9%	$326.1M+92.0%	$169.8M+51.6%	$112.1M-1.3%	$113.5M
Current Assets	$548.0M-26.5%	$745.1M+46.1%	$510.0M+2.3%	$498.3M-42.5%	$866.0M+32.9%	$651.6M+59.5%	$408.6M-14.5%	$478.0M+22.2%	$391.1M+60.9%	$243.1M-3.8%	$252.6M+17.9%	$214.3M+100.7%	$106.8M+75.2%	$60.9M-26.3%	$82.6M
Cash & Equivalents	$158.5M-42.7%	$276.8M+80.5%	$153.3M+47.2%	$104.1M-82.2%	$585.6M+485.8%	$100.0M+27.8%	$78.2M-41.0%	$132.5M+144.8%	$54.1M+50.6%	$35.9M-33.6%	$54.1M+44.3%	$37.5M+199.8%	$12.5M0.0%	$12.5M-72.9%	$46.2M
Short-Term Investments	$79.9M-61.6%	$207.8M+65.9%	$125.3M-32.1%	$184.5M+160.5%	$70.8M-83.2%	$421.7M+97.3%	$213.7M-14.8%	$250.9M-2.4%	$257.2M+88.2%	$136.7M+34.0%	$102.0M-14.4%	$119.1M+99.8%	$59.6M+92.9%	$30.9M+3.1%	$30.0M
Inventory	$152.9M+22.0%	$125.3M+20.1%	$104.4M+8.6%	$96.1M-2.5%	$98.5M+52.4%	$64.7M+10.9%	$58.3M+20.0%	$48.6M+17.3%	$41.4M+32.4%	$31.3M-49.3%	$61.6M+110.7%	$29.3M+88.1%	$15.6M+28.8%	$12.1M+870.0%	$1.2M
Accounts Receivable	$124.1M+9.5%	$113.3M+7.3%	$105.6M+7.3%	$98.4M+2.2%	$96.3M+81.6%	$53.0M+11.6%	$47.5M+25.1%	$38.0M+20.0%	$31.7M+5.7%	$29.9M+15.8%	$25.9M+15.6%	$22.4M+53.3%	$14.6M+235.2%	$4.4M+106.0%	$2.1M
Long-Term Investments	$0	$0-100.0%	$2.4M-93.5%	$37.2M	$0-100.0%	$95.5M+47.3%	$64.8M+150.5%	$25.9M-56.9%	$60.0M	$0-100.0%	$13.5M-44.9%	$24.4M	$0	$0	$0
Goodwill	$20.2M	$0-100.0%	$163.2M0.0%	$163.2M+12.4%	$145.2M+45.9%	$99.5M0.0%	$99.5M+60.5%	$62.0M+12.4%	$55.2M+18.1%	$46.7M+51.4%	$30.9M+30.0%	$23.8M+130.1%	$10.3M+24.5%	$8.3M	$0
Total Liabilities	$571.8M-26.2%	$775.2M+10.1%	$704.3M-22.3%	$906.2M-32.6%	$1.3B+105.4%	$654.8M+37.5%	$476.1M+29.3%	$368.1M+5.5%	$348.9M+102.3%	$172.5M+1.9%	$169.3M+9.3%	$154.9M+20.5%	$128.6M+178.3%	$46.2M-29.2%	$65.2M
Current Liabilities	$120.6M-61.1%	$309.9M+218.2%	$97.4M-34.1%	$147.8M-71.6%	$521.1M+105.7%	$253.3M+135.3%	$107.7M+77.5%	$60.7M+7.9%	$56.2M+25.4%	$44.8M-70.1%	$149.8M+7.0%	$140.0M+14.8%	$121.9M+761.4%	$14.2M-55.6%	$31.9M
Non-Current Liabilities	$451.2M-3.0%	$465.2M-23.3%	$606.9M-20.0%	$758.4M-7.9%	$823.8M+105.2%	$401.5M+9.0%	$368.4M+19.8%	$307.5M+5.1%	$292.7M+129.3%	$127.7M+552.8%	$19.6M+31.1%	$14.9M+125.1%	$6.6M-79.3%	$32.0M-3.8%	$33.3M
Long-Term Debt	$372.2M-3.0%	$383.5M-26.6%	$522.4M-24.2%	$689.5M	N/A	N/A	N/A	N/A	N/A	$108.7M+4.5%	$104.0M+0.9%	$103.1M	N/A	$25.2M+35.9%	$18.5M
Total Equity	$693.1M-11.0%	$778.3M-10.5%	$870.1M+12.3%	$775.0M+6.1%	$730.4M+17.9%	$619.7M+74.6%	$354.9M+10.5%	$321.2M+14.9%	$279.5M+27.6%	$219.0M+0.3%	$218.4M+27.6%	$171.1M+314.9%	$41.2M-37.4%	$65.9M+36.4%	$48.3M
Retained Earnings	-$199.3M+3.4%	-$206.4M-93.2%	-$106.8M+28.2%	-$148.8M+29.8%	-$211.9M+16.5%	-$253.9M+36.4%	-$399.4M-2.9%	-$388.2M+0.2%	-$389.1M-12.4%	-$346.2M-12.3%	-$308.3M+0.6%	-$310.1M-4.6%	-$296.4M-27.5%	-$232.5M-29.0%	-$180.2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.2B-19.1%	$1.2B-23.8%	$1.3B-18.6%	$1.3B-14.7%	$1.5B-6.7%	$1.6B+0.2%	$1.6B-1.3%	$1.5B-0.8%
Current Assets	$615.2M-17.5%	$515.0M-32.2%	$548.0M-26.5%	$562.8M-18.4%	$745.6M+17.9%	$760.0M+39.9%	$745.1M+46.1%	$690.0M+54.3%
Cash & Equivalents	$205.9M-31.5%	$144.3M-49.1%	$158.5M-42.7%	$147.6M-40.0%	$300.5M+21.6%	$283.6M+54.1%	$276.8M+80.5%	$246.0M+148.2%
Short-Term Investments	$45.2M-68.9%	$57.9M-72.4%	$79.9M-61.6%	$98.7M-52.5%	$145.4M-7.5%	$210.0M+48.1%	$207.8M+65.9%	$207.8M+52.7%
Inventory	$134.6M-9.2%	$150.4M+12.4%	$152.9M+22.0%	$157.7M+41.0%	$148.2M+43.2%	$133.8M+38.2%	$125.3M+20.1%	$111.9M+15.9%
Accounts Receivable	$132.4M+15.8%	$125.6M+19.9%	$124.1M+9.5%	$115.3M+14.5%	$114.4M+9.2%	$104.7M+3.1%	$113.3M+7.3%	$100.7M+3.8%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0-100.0%	$0
Goodwill	$19.6M-3.2%	$19.8M-8.1%	$20.2M	$20.3M	$20.3M-87.6%	$21.5M-86.8%	$0-100.0%	$0-100.0%
Total Liabilities	$572.0M-26.6%	$554.6M-29.6%	$571.8M-26.2%	$570.4M-26.1%	$779.5M+1.6%	$788.1M+14.0%	$775.2M+10.1%	$772.1M+9.8%
Current Liabilities	$122.0M-61.0%	$108.8M-65.4%	$120.6M-61.1%	$107.1M-65.1%	$313.2M+237.9%	$314.7M+236.8%	$309.9M+218.2%	$306.4M+227.1%
Non-Current Liabilities	$450.0M-3.5%	$445.9M-5.8%	$451.2M-3.0%	$463.3M-0.5%	$466.3M-30.9%	$473.4M-20.8%	$465.2M-23.3%	$465.7M-23.6%
Long-Term Debt	$363.1M-37.4%	$367.7M-37.0%	$372.2M-3.0%	$376.7M	$580.5M	$583.4M	$383.5M-26.6%	N/A
Total Equity	$672.0M-11.3%	$653.9M-18.1%	$693.1M-11.0%	$727.2M-3.0%	$757.8M-13.8%	$798.5M-10.5%	$778.3M-10.5%	$749.6M-9.9%
Retained Earnings	-$191.8M+7.1%	-$196.4M+2.5%	-$199.3M+3.4%	-$201.0M+9.6%	-$206.4M-161.5%	-$201.5M-106.0%	-$206.4M-93.2%	-$222.4M-68.9%

PCRX Cash Flow Statement

PCRX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$187.7M	$152.0M-19.7%	$189.4M+22.5%	$154.6M+6.5%	$145.3M+15.6%	$125.7M+63.2%	$77.0M+9.2%	$70.5M+44.3%	$48.9M+174.8%	$17.8M-46.8%	$33.5M+19.4%	$28.0M+5.5%	$26.6M+160.6%	-$43.8M+37.5%	-$70.1M-126.2%	-$31.0M
Depreciation & Amortization	N/A	$91.0M+15.5%	$78.8M+4.2%	$75.6M-17.4%	$91.5M+220.5%	$28.5M+43.4%	$19.9M+1.7%	$19.6M+48.7%	$13.2M-4.8%	$13.8M+7.1%	$12.9M+12.6%	$11.5M+14.3%	$10.0M+74.6%	$5.7M+1.8%	$5.6M+30.9%	$4.3M
Stock-Based Compensation	N/A	$57.5M+12.4%	$51.2M+6.8%	$47.9M-0.4%	$48.1M+13.8%	$42.2M+5.8%	$39.9M+18.6%	$33.6M+6.1%	$31.7M+0.4%	$31.6M+1.1%	$31.2M-6.4%	$33.4M+34.4%	$24.8M+115.6%	$11.5M+141.1%	$4.8M+91.6%	$2.5M
Capital Expenditures	$8.1M	$15.3M+44.2%	$10.6M-29.8%	$15.2M-49.6%	$30.1M-34.4%	$45.9M+21.3%	$37.8M+272.1%	$10.2M-30.0%	$14.5M-24.7%	$19.3M-22.0%	$24.7M-38.7%	$40.3M+75.3%	$23.0M+88.8%	$12.2M-33.3%	$18.3M+196.0%	$6.2M
Free Cash Flow	$179.5M	$136.7M-23.5%	$178.8M+28.1%	$139.5M+21.1%	$115.2M+44.3%	$79.9M+103.5%	$39.2M-35.0%	$60.4M+75.7%	$34.4M+2419.8%	-$1.5M-116.9%	$8.7M+171.2%	-$12.3M-442.8%	$3.6M+106.4%	-$56.0M+36.6%	-$88.4M-137.8%	-$37.2M
Investing Cash Flow	$94.1M	$99.5M+219.5%	-$83.3M-207.4%	$77.5M+134.4%	-$225.2M-983.1%	-$20.8M+92.5%	-$277.6M-116.1%	-$128.5M-724.5%	$20.6M+109.2%	-$223.8M	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	-$376.2M	-$369.6M-2228.8%	$17.4M+109.5%	-$183.0M+54.4%	-$401.5M-205.5%	$380.7M+71.2%	$222.3M+5957.3%	$3.7M-59.0%	$9.0M-96.0%	$224.2M	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$148.3M	$148.3M+493.3%	$25.0M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$57.5M+378.4%	$25.7M-27.6%	$43.7M+31.9%	$60.8M+12.8%	$12.0M-77.4%	$35.5M-27.8%	$33.1M-30.4%	$53.9M+21.3%
Depreciation & Amortization	$21.3M-22.0%	$21.3M+0.8%	$21.3M+0.5%	$21.2M+4.4%	$27.3M+45.2%	$21.2M+14.9%	$21.2M+14.9%	$20.3M+10.3%
Stock-Based Compensation	$15.0M-3.3%	$13.5M-7.0%	N/A	$14.0M+5.7%	$15.5M+23.5%	$14.6M+10.7%	N/A	$13.2M+5.6%
Capital Expenditures	$1.3M-50.5%	$2.7M-68.1%	$218K-89.7%	$3.9M-5.4%	$2.7M+69.6%	$8.5M+201.4%	$2.1M+17.8%	$4.1M+20.6%
Free Cash Flow	$56.1M+502.5%	$23.0M-14.7%	$43.5M+40.2%	$57.0M+14.3%	$9.3M-82.0%	$26.9M-41.8%	$31.0M-32.3%	$49.8M+21.4%
Investing Cash Flow	$11.8M-81.1%	$19.4M+175.9%	$19.3M+5353.5%	$43.6M+183.6%	$62.2M+508.6%	-$25.6M-65.0%	-$368K-104.4%	-$52.2M-1101.4%
Financing Cash Flow	-$7.7M+86.7%	-$59.4M-1883.9%	-$51.7M-2542.0%	-$257.5M-8950.1%	-$57.5M-330.2%	-$3.0M-6.3%	-$2.0M-9.9%	-$2.8M+89.8%
Share Buybacks	$0-100.0%	$50.0M	$48.2M	$50.0M	$50.0M	$0	$0	$0

Not reported in any period shown, so not listed: Dividends Paid.

PCRX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PCRX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	79.4%+3.7pp	75.7%+3.0pp	72.6%+2.5pp	70.1%-4.0pp	74.1%+1.4pp	72.7%-2.0pp	74.7%+0.4pp	74.3%+4.9pp	69.3%+9.2pp	60.2%-11.0pp	71.2%+10.3pp	60.8%+24.8pp	36.0%+18.2pp	17.8%+24.5pp	-6.7%
Operating Margin	2.6%+13.1pp	-10.5%-23.5pp	13.0%+4.0pp	9.0%-7.6pp	16.6%+5.8pp	10.8%+8.3pp	2.5%-2.2pp	4.7%+13.4pp	-8.7%+2.9pp	-11.6%-15.4pp	3.8%+6.4pp	-2.6%+59.7pp	-62.3%	-126.1%	-249.2%
Net Margin	1.0%+15.2pp	-14.2%-20.4pp	6.2%+3.8pp	2.4%-5.4pp	7.8%-26.1pp	33.9%+36.5pp	-2.6%-2.5pp	-0.1%+14.7pp	-14.9%-1.1pp	-13.7%-14.5pp	0.8%+7.7pp	-6.9%+67.8pp	-74.7%	-133.8%	-276.2%
Return on Equity	1.0%+13.8pp	-12.8%-17.6pp	4.8%+2.8pp	2.1%-3.7pp	5.8%-17.7pp	23.5%+26.6pp	-3.1%-2.9pp	-0.1%+15.1pp	-15.3%+2.1pp	-17.3%-18.2pp	0.9%+8.9pp	-8.0%+146.9pp	-154.9%-75.5pp	-79.4%+10.4pp	-89.8%
Return on Assets	0.5%+7.0pp	-6.4%-9.1pp	2.7%+1.7pp	0.9%-1.1pp	2.0%-9.4pp	11.4%+12.8pp	-1.3%-1.3pp	-0.1%+6.7pp	-6.8%+2.9pp	-9.7%-10.2pp	0.5%+4.7pp	-4.2%+33.4pp	-37.6%+9.0pp	-46.7%-8.5pp	-38.2%
Current Ratio	4.54+2.1x	2.40-2.8x	5.24+1.9x	3.37+1.7x	1.66-0.9x	2.57-1.2x	3.79-4.1x	7.88+0.9x	6.96+1.5x	5.42+3.7x	1.69+0.2x	1.53+0.7x	0.88-3.4x	4.30+1.7x	2.59
Debt-to-Equity	0.540.0x	0.49-0.1x	0.60-0.3x	0.89-1.0x	1.84+0.8x	1.06-0.3x	1.34+0.2x	1.15-0.1x	1.25+0.8x	0.500.0x	0.48-0.1x	0.60-2.5x	3.12+2.7x	0.380.0x	0.38
Asset Turnover	0.57+0.1x	0.450.0x	0.430.0x	0.40+0.1x	0.26-0.1x	0.34-0.2x	0.510.0x	0.490.0x	0.46-0.2x	0.71+0.1x	0.640.0x	0.61+0.1x	0.50+0.2x	0.35+0.2x	0.14
FCF Margin	18.8%-6.7pp	25.5%+4.8pp	20.7%+3.4pp	17.3%+2.5pp	14.8%+5.6pp	9.1%-5.2pp	14.3%+4.1pp	10.2%+10.7pp	-0.5%-3.7pp	3.2%+8.1pp	-4.9%-6.7pp	1.8%+67.3pp	-65.5%	-226.1%	-236.9%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	77.0%-0.4pp	79.5%-0.2pp	79.5%+0.8pp	80.9%+4.0pp	77.4%+2.3pp	79.7%+8.1pp	78.7%+5.0pp	77.0%+1.2pp
Operating Margin	2.2%-2.5pp	3.9%+2.7pp	1.2%-12.0pp	3.5%+86.3pp	4.7%-11.2pp	1.2%-6.7pp	13.2%-5.1pp	-82.8%-93.6pp
Net Margin	2.4%+5.1pp	1.6%-1.2pp	0.8%-7.7pp	3.0%+88.1pp	-2.7%-13.3pp	2.9%-2.5pp	8.6%-5.2pp	-85.1%-91.7pp
Return on Equity	0.7%+1.3pp	0.4%-0.2pp	0.2%-1.8pp	0.8%+19.9pp	-0.6%-2.8pp	0.6%-0.4pp	2.1%-0.8pp	-19.1%-20.4pp
Return on Assets	0.4%+0.7pp	0.2%-0.1pp	0.1%-0.9pp	0.4%+9.8pp	-0.3%-1.5pp	0.3%-0.3pp	1.0%-0.6pp	-9.4%-10.1pp
Current Ratio	5.04+2.7x	4.73+2.3x	4.54+2.1x	5.26+3.0x	2.38-4.4x	2.41-3.4x	2.40-2.8x	2.25-2.5x
Debt-to-Equity	0.54-0.2x	0.56-0.2x	0.540.0x	0.52-0.5x	0.77-0.1x	0.730.0x	0.49-0.1x	1.03+0.2x
Asset Turnover	0.150.0x	0.150.0x	0.160.0x	0.140.0x	0.120.0x	0.110.0x	0.120.0x	0.110.0x
FCF Margin	29.2%+24.0pp	12.9%-3.0pp	22.1%+5.5pp	31.7%+2.2pp	5.1%-23.9pp	15.9%-11.8pp	16.6%-8.7pp	29.6%+4.5pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Pacira BioSciences, Inc. PCRX	FY2025	$726.4M	$7.0M	1.0%	$1.4B	53/100
Collegium Pharmaceutical, Inc. COLL	FY2025	$780.6M	$63.0M	8.1%	$719.2M	65/100
Dynavax Technologies Corporation DVAX	FY2024	$277.2M	$27.3M	9.8%	$1.8B	54/100
Avadel Pharmaceuticals plc AVDL	FY2024	$169.1M	-$48.8M	-28.9%	$2.1B	53/100
Harrow, Inc. HROW	FY2025	$272.3M	-$5.1M	-1.9%	$1.1B	52/100
Amphastar Pharmaceuticals, Inc. AMPH	FY2025	$719.9M	$98.1M	13.6%	$1.1B	70/100

Where Pacira BioSciences, Inc. Ranks

Frequently Asked Questions

What is Pacira BioSciences, Inc.'s annual revenue?

Pacira BioSciences, Inc. (PCRX) reported $726.4M in total revenue for fiscal year 2025. This represents a 3.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Pacira BioSciences, Inc.'s revenue growing?

Pacira BioSciences, Inc. (PCRX) revenue grew by 3.6% year-over-year, from $701.0M to $726.4M in fiscal year 2025.

Is Pacira BioSciences, Inc. profitable?

Yes, Pacira BioSciences, Inc. (PCRX) reported a net income of $7.0M in fiscal year 2025, with a net profit margin of 1.0%.

What is Pacira BioSciences, Inc.'s EBITDA?

Pacira BioSciences, Inc. (PCRX) had EBITDA of $110.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Pacira BioSciences, Inc. have?

As of fiscal year 2025, Pacira BioSciences, Inc. (PCRX) had $158.5M in cash and equivalents against $372.2M in long-term debt.

What is Pacira BioSciences, Inc.'s gross margin?

Pacira BioSciences, Inc. (PCRX) had a gross margin of 79.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Pacira BioSciences, Inc.'s operating margin?

Pacira BioSciences, Inc. (PCRX) had an operating margin of 2.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Pacira BioSciences, Inc.'s net profit margin?

Pacira BioSciences, Inc. (PCRX) had a net profit margin of 1.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Pacira BioSciences, Inc.'s return on equity (ROE)?

Pacira BioSciences, Inc. (PCRX) has a return on equity of 1.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Pacira BioSciences, Inc.'s free cash flow?

Pacira BioSciences, Inc. (PCRX) generated $136.7M in free cash flow during fiscal year 2025. This represents a -23.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Pacira BioSciences, Inc.'s operating cash flow?

Pacira BioSciences, Inc. (PCRX) generated $152.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Pacira BioSciences, Inc.'s total assets?

Pacira BioSciences, Inc. (PCRX) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Pacira BioSciences, Inc.'s capital expenditures?

Pacira BioSciences, Inc. (PCRX) invested $15.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Pacira BioSciences, Inc. spend on research and development?

Pacira BioSciences, Inc. (PCRX) invested $117.3M in research and development during fiscal year 2025.

Does Pacira BioSciences, Inc. buy back shares?

Yes, Pacira BioSciences, Inc. (PCRX) spent $148.3M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Pacira BioSciences, Inc. have outstanding?

Pacira BioSciences, Inc. (PCRX) had 40M shares outstanding as of fiscal year 2025.

What is Pacira BioSciences, Inc.'s current ratio?

Pacira BioSciences, Inc. (PCRX) had a current ratio of 4.54 as of fiscal year 2025, which is generally considered healthy.

What is Pacira BioSciences, Inc.'s debt-to-equity ratio?

Pacira BioSciences, Inc. (PCRX) had a debt-to-equity ratio of 0.54 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Pacira BioSciences, Inc.'s return on assets (ROA)?

Pacira BioSciences, Inc. (PCRX) had a return on assets of 0.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Pacira BioSciences, Inc.'s P/E ratio?

Pacira BioSciences, Inc. (PCRX) trades at 99.2x earnings, its market capitalization divided by net income of $14.6M net income, trailing 12 months to June 30, 2026. The market capitalization is $1.4B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Pacira BioSciences, Inc.'s price-to-sales ratio?

Pacira BioSciences, Inc. (PCRX) trades at 1.9x sales, its market capitalization divided by revenue of $746.2M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.4B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Pacira BioSciences, Inc.'s Altman Z-Score?

Pacira BioSciences, Inc. (PCRX) has an Altman Z-Score of 2.33, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Pacira BioSciences, Inc.'s Piotroski F-Score?

Pacira BioSciences, Inc. (PCRX) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Pacira BioSciences, Inc.'s earnings high quality?

Pacira BioSciences, Inc. (PCRX) reported $7.0M of net income while generating $152.0M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Pacira BioSciences, Inc. cover its interest payments?

Pacira BioSciences, Inc. (PCRX) has an interest coverage ratio of 1.10x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Pacira BioSciences, Inc.?

Pacira BioSciences, Inc. (PCRX) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.